Cargando…
S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
BACKGROUND: Cancer cachexia, occurring in ~ 80% pancreatic cancer (PC) patients overall, is a paraneoplastic syndrome mediated by cancer-induced systemic inflammation and characterized by weight loss and skeletal muscle wasting. Identifying clinically relevant PC-derived pro-inflammatory factors wit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242984/ https://www.ncbi.nlm.nih.gov/pubmed/37280516 http://dx.doi.org/10.1186/s12885-023-11009-8 |
_version_ | 1785054334228103168 |
---|---|
author | Liao, Wei-Chih Chen, Chih-Ta Tsai, You-Shu Wang, Xin-Ya Chang, Yen-Tzu Wu, Ming-Shiang Chow, Lu-Ping |
author_facet | Liao, Wei-Chih Chen, Chih-Ta Tsai, You-Shu Wang, Xin-Ya Chang, Yen-Tzu Wu, Ming-Shiang Chow, Lu-Ping |
author_sort | Liao, Wei-Chih |
collection | PubMed |
description | BACKGROUND: Cancer cachexia, occurring in ~ 80% pancreatic cancer (PC) patients overall, is a paraneoplastic syndrome mediated by cancer-induced systemic inflammation and characterized by weight loss and skeletal muscle wasting. Identifying clinically relevant PC-derived pro-inflammatory factors with cachexigenic potential may provide novel insights and therapeutic strategies. METHODS: Pro-inflammatory factors with cachexigenic potential in PC were identified by bioinformatic analysis. The abilities of selected candidate factors in inducing skeletal muscle atrophy were investigated. Expression levels of candidate factors in tumors and sera was compared between PC patients with and without cachexia. Associations between serum levels of the candidates and weight loss were assessed in PC patients. RESULTS: S100A8, S100A9, and S100A8/A9 were identified and shown to induce C2C12 myotube atrophy. Tumors of PC patients with cachexia had markedly elevated expression of S100A8 (P = 0.003) and S100A9 (P < 0.001). PC patients with cachexia had significantly higher serum levels of S100A8, S100A9 and S100A8/A9. Serum levels of these factors positively correlated with percentage of weight loss [correlation coefficient: S100A8: 0.33 (P < 0.001); S100A9: 0.30 (P < 0.001); S100A8/A9: 0.24 (P = 0.004)] and independently predicted the occurrence of cachexia [adjusted odds ratio (95% confidence interval) per 1ng/ml increase: S100A8 1.11 (1.02–1.21), P = 0.014; S100A9 1.10 (1.04–1.16), P = 0.001; per 1 µg/ml increase: S100A8/A9 1.04 (1.01–1.06), P = 0.009]. CONCLUSIONS: Atrophic effects of S100A8, S100A9, and S100A8/A9 indicated them as potential pathogenic factors of PC-induced cachexia. In addition, the correlation with the degree of weight loss and prediction of cachexia in PC patients implicated their potential utility in the diagnosis of PC-induced cachexia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11009-8. |
format | Online Article Text |
id | pubmed-10242984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102429842023-06-07 S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia Liao, Wei-Chih Chen, Chih-Ta Tsai, You-Shu Wang, Xin-Ya Chang, Yen-Tzu Wu, Ming-Shiang Chow, Lu-Ping BMC Cancer Research BACKGROUND: Cancer cachexia, occurring in ~ 80% pancreatic cancer (PC) patients overall, is a paraneoplastic syndrome mediated by cancer-induced systemic inflammation and characterized by weight loss and skeletal muscle wasting. Identifying clinically relevant PC-derived pro-inflammatory factors with cachexigenic potential may provide novel insights and therapeutic strategies. METHODS: Pro-inflammatory factors with cachexigenic potential in PC were identified by bioinformatic analysis. The abilities of selected candidate factors in inducing skeletal muscle atrophy were investigated. Expression levels of candidate factors in tumors and sera was compared between PC patients with and without cachexia. Associations between serum levels of the candidates and weight loss were assessed in PC patients. RESULTS: S100A8, S100A9, and S100A8/A9 were identified and shown to induce C2C12 myotube atrophy. Tumors of PC patients with cachexia had markedly elevated expression of S100A8 (P = 0.003) and S100A9 (P < 0.001). PC patients with cachexia had significantly higher serum levels of S100A8, S100A9 and S100A8/A9. Serum levels of these factors positively correlated with percentage of weight loss [correlation coefficient: S100A8: 0.33 (P < 0.001); S100A9: 0.30 (P < 0.001); S100A8/A9: 0.24 (P = 0.004)] and independently predicted the occurrence of cachexia [adjusted odds ratio (95% confidence interval) per 1ng/ml increase: S100A8 1.11 (1.02–1.21), P = 0.014; S100A9 1.10 (1.04–1.16), P = 0.001; per 1 µg/ml increase: S100A8/A9 1.04 (1.01–1.06), P = 0.009]. CONCLUSIONS: Atrophic effects of S100A8, S100A9, and S100A8/A9 indicated them as potential pathogenic factors of PC-induced cachexia. In addition, the correlation with the degree of weight loss and prediction of cachexia in PC patients implicated their potential utility in the diagnosis of PC-induced cachexia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11009-8. BioMed Central 2023-06-06 /pmc/articles/PMC10242984/ /pubmed/37280516 http://dx.doi.org/10.1186/s12885-023-11009-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liao, Wei-Chih Chen, Chih-Ta Tsai, You-Shu Wang, Xin-Ya Chang, Yen-Tzu Wu, Ming-Shiang Chow, Lu-Ping S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
title | S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
title_full | S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
title_fullStr | S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
title_full_unstemmed | S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
title_short | S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
title_sort | s100a8, s100a9 and s100a8/a9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242984/ https://www.ncbi.nlm.nih.gov/pubmed/37280516 http://dx.doi.org/10.1186/s12885-023-11009-8 |
work_keys_str_mv | AT liaoweichih s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia AT chenchihta s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia AT tsaiyoushu s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia AT wangxinya s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia AT changyentzu s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia AT wumingshiang s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia AT chowluping s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia |